Last reviewed · How we verify

Organophosphate poisoning — Treatment Landscape & Competitive Intelligence

Organophosphate poisoning (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Organophosphate poisoning, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pralidoxime Chloride (Autoinjector) PRALIDOXIME Baxter Cholinesterase Reactivator Acetylcholinesterase 1964-01-01
Toxogonin Toxogonin Aya Sabry Mohamed Mohamed Acetylcholinesterase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Organophosphate poisoning
  2. Aya Sabry Mohamed Mohamed · 1 drug in Organophosphate poisoning
  3. Baxter · 1 drug in Organophosphate poisoning

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Organophosphate poisoning:

Cite this brief

Drug Landscape (2026). Organophosphate poisoning — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/organophosphate-poisoning. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing